Doctor speaking with patient. Image credit: Canva
Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor, and most tumors come back aggressively within months or years of treatment. Researchers are seeking standard treatment for people whose glioblastoma has returned after radiation therapy.
A clinical trial led by Peter Mathen, M.D., Staff Clinician in the Radiation Oncology Branch, is researching a safe schedule for administering radiation to adults with glioblastoma tumors that have returned after initial radiation treatment.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06344130
NCI Protocol ID: IRB001859
Official Title: A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
